Feasibility of Ayurveda in Patients With Mild-to-Moderate COVID-19: A Community-Based Participatory Research

A Community-Based Participatory Research to Assess the Feasibility of Ayurveda Intervention in Patients With Mild-to-Moderate COVID-19

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04716647

Enrollment

Registered

2021-01-20

Start date

2020-10-09

Completion date

2020-12-18

Last updated

2021-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Keywords

Ayurveda Intervention, Community Based Participatory Research

Brief summary

Innovative strategies are required to manage COVID-19 in the communities. Back to Roots community based project was a collaborative, pilot intervention program in British Asian community to assess the efficacy and safety of Ayurveda intervention in relieving symptoms of mild-to-moderate COVID-19.

Interventions

OTHERAyurveda

Dosage was used in common range (Ashwagandha: Doses range from 250 mg to 5 g; Giloy: range from 500mg to 1g; Tulsi: 500mg-1g) Dosage were altered based on age, weight and severity of symptoms.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Intervention model description

Community Based Participatory Research

Eligibility

Sex/Gender

ALL

Age

20 Years to 70 Years

Healthy volunteers

Inclusion criteria

* With SARS-CoV-2 infection confirmed through reverse transcription followed by polymerase chain reaction (RT- PCR), * With mild or moderate manifestations of COVID-19 * Willing to participate, and consent by signing the informed consent and * not involved in another clinical trial during the study

Exclusion criteria

* Patients suffering from severe COVID-19 Disease as per World Health Organisation criteria (REF) * Any of the known COVID-19 complications and emergency procedures which may require shift/admission in hospital for oxygen support or intensive care unit * Patients with ongoing immunosuppressive therapy for any reasons * Active cancer diagnosis, on palliative treatment or requiring current therapy with antimetabolic agents, immunotherapy or radiotherapy. * Pregnancy and lactation * Ayurveda practitioner decision that involvement in the study is not in the patient's best interest

Design outcomes

Primary

Measure	Time frame	Description
Time to clinical recovery	Up to 14-days	To evaluate the therapeutic efficacy, mean days for clinical recovery were recorded from AiM Covid Application
Proportion of patient with negative conversion in nasopharyngeal swab	Up to 14 days	To evaluate the therapeutic efficacy, promotion of patients were recorded through AiM Covid application

Secondary

Measure	Time frame	Description
Clinical Outcome	Up to 14-days	Clinical Outcome was recorded on 7-pont ordinal scale of COVID-19

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026